Compare Roundhill Russell 2000 0DTE Covered Call Strat ETF (RDTE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Russell 2000 0DTE Covered Call Strat ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $26.12 (market cap $159.33M), while State Street SPDR S&P Biotech ETF trades at $153.85 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 63.5× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Roundhill Russell 2000 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Russell 2000 0DTE Covered Call Strat ETF for 54 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RDTE | XBI | |
|---|---|---|
Market Cap | $159.33M | $10.11B |
Volume | 248,058 | 12,903,266 |
Sector | Income / Options Overlay | Broad Market / Factor |
52-Week High | $33.66 | $169.55 |
52-Week Low | $25.96 | $104.99 |
Typical Hold Time | 54 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RDTE trades at $26.12, showing minimal daily movement with a slight decline of 0.08%. The technical outlook is bearish, driven by negative moving average signals, while oscillators are neutral. The ETF has a history of frequent, small dividend payments, but key valuation and profitability ratios are unavailable. Recent news highlights concerns about capital erosion risk in covered-call strategies compared to peers.
The outlook for RDTE is cautious due to bearish technicals and media skepticism about its income strategy's sustainability. Investment appeal hinges on high yield, but risks include capital depreciation and underperformance versus benchmarks. Investors should weigh income generation against potential long-term value erosion in a competitive ETF landscape.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Russell 2000 0DTE Covered Call Strat ETF
RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
